# Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)

> **NCT00952341** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 421 (actual)

## Conditions studied

- Chemotherapy-induced Nausea and Vomiting (CINV)

## Interventions

- **DRUG:** aprepitant
- **DRUG:** Comparator: Placebo to aprepitant
- **DRUG:** dexamethasone
- **DRUG:** granisetron
- **DRUG:** dexamethasone

## Key facts

- **NCT ID:** NCT00952341
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08-25
- **Primary completion:** 2010-04-04
- **Final completion:** 2010-05-05
- **Target enrollment:** 421 (ACTUAL)
- **Last updated:** 2017-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00952341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00952341, "Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00952341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*